among others. Mutations in nucleophosmin 1 (NPM1; localised on 5q32) are the second most common mutations in acute myeloid leukaemia (AML) after FLT3 mutations, 3 and are associated with distinctive transcriptional signatures and a reduced ability of NPM1 to shuttle between the nucleolus, nucleus and cytoplasm. 4 NPM is also thought to have a tumour-suppressor function in myeloid haematopoiesis, where a reduction in wild-type NPM may contribute to tumourigenesis; 4 however, the exact role is still unclear. Most recently, Georgiou et al. 5 reported a case of a CML patient who achieved complete cytogenetic and molecular response on 400 mg imatinib daily, and subsequently developed AML with normal karyotype and mutated NPM1/negative FLT3-ITD (NPM1 mut /FLT3-ITD neg ). This patient achieved a complete molecular response 12 months after the initiation of imatinib treatment; however, after 43 months that patient was subsequently diagnosed with AML M2 (FAB classification). AML karyotype analysis was normal (46,XY[20]) with BCR-ABL1 transcripts undetectable by both real-time quantitative PCR and nested PCR. Further PCR analysis identified NPM1 mut type B without FLT3-ITD. Interestingly, subsequent testing demonstrated that the NPM1 mutation was present at low levels 12 months prior to AML diagnosis, suggesting a possible role in the transformation of CML. NPM1 mutations have also been reported in Philadelphia chromosome (Ph þ ) AML, 6 indicating an ability to cooperate with BCR-ABL1 in leukaemic transformation. One case of NPM1 mut myeloid BC-CML has also previously been reported in the literature. 7 In this particular case, the NPM1 mutation did appear to function in the transformation of BC-CML, as the mutation was found in conjunction with the BCR-ABL1 rearrangement in almost all blastic leukaemic cells. However, other studies have failed to definitively show NPM1 mutations in CML (both CP- 4, 8 and BC-CML 1,6 ) using various techniques, but CP-CML patients at risk of disease progression have not been fully interrogated. To investigate whether NPM1 mutations have a role in BC-CML or early in the progression of CP-CML, and in particular whether such mutations may be associated with poor-risk CP-CML, we determined NPM1 mutations status in a cohort of BC-and CP-CML patients identified by low OCT-1 activity. 9 Here we report the screening of our BC-CML patient cohort for mutations in the NPM1 gene locus. Genomic DNA collected from 14 BC-CML patient's presenting to our centre was screened using a fluorescence-based PCR assay, capillary electrophoresis (ABI Prism 3100 Genetic Analyser, Applied Biosystems, Carlsbad, CA, USA) and GeneScan analysis (Applied Biosystems), as previously described. 10 Out of these 14 patients, five patients were diagnosed with BC, five progressed from CP-CML and four were referred from other centres with BC. A single set of primers was used to screen for the most common NPM1 mutations (a fournucleotide insertion located in nt959 or 965 of exon 12, covering all known NPM1 mutations), 4 producing a 232-bp product for wild-type NPM1 or 236-bp product for NPM1 mut . We observed no NPM1 mutations in the 14 BC-CML patients analysed using this assay, which was consistent with the results of previous studies. 1, 6 We then extended the screen to a cohort of CP-CML patients (n ¼ 33) to determine their NPM1 mutation status, including 17 poor-risk patients defined by low OCT-1 activity values (omedian, 7.2 ng/200 000 cells). This group of poor-risk patients are highly associated with the development of kinase domain mutations and disease progression. 9 Furthermore, patients with low OCT-1 activity have a poorer rate of achievement of major and complete molecular response up to 5 years, and lower event-free, transformation-free and overall survival. Once again we detected no NPM1 mutations in any of the 33 CP-CML patients, which was consistent with previous small-cohort CP-CML studies. 4, 8 Included in our CP-CML cohort was a single patient who progressed from CP-to BC-CML 4 months after starting imatinib therapy. Matched samples at diagnosis and BC progression were available and tested with this patient who remained NPM1 mut negative at both time points.
Our study and those of others show that mutations in the NPM1 gene are rarely associated with CP-or BC-CML patients, including those at risk of disease progression (low OCT-1 activity). The case report of CML transformation to AML associated with NPM1 mutation described by Georgiou et al.
5 represents a very rare case. Such transformation of CML to AML (distinct from Ph þ BC-CML) is extremely rare and only a handful of cases have been reported. [11] [12] [13] [14] [15] As the NPM1 mutation status was not obtained in these cases, it is not possible to ascertain whether it is predictive of transformation to AML. Therefore, we conclude that NPM1 mutations do not have a role in CML disease initiation or progression to BC. This suggests that the events that cooperate with BCR-ABL1 in acute transformation are distinct from those that drive the leukaemogenic process in a large subset of AML cases associated with normal karyotype and a high frequency of NPM1 mutations. Telomeres are protective chromosomal end structures composed of G-rich nucleotide repeats and an associated protein complex termed shelterin. Because of incomplete replication, telomeric repeats are lost with every cell division, and this telomere attrition is involved in cell senescence and cancer (reviewed in Artandi and DePinho 1 ). Short, unprotected telomeres are erroneously fused by the DNA-repair system, which gives rise to aneuploidies or structural chromosome rearrangements through chromosome fusion-bridge-breakage cycles. Thus, telomere dysfunction can drive genomic instability during tumorigenesis.
Telomeres and chromosomal instability in chronic lymphocytic leukemia
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In chronic lymphocytic leukemia (CLL), short telomeres have been associated with poor-prognosis cytogenetics.
2,3 Besides telomere length, the functional state of telomeres depends on several molecular factors. Telomeres can be regenerated by telomerase and are protected from fusions by shelterin proteins. Detailed investigations assessing all together the expression of telomerase and shelterin genes, telomere length, recurrent aberrations and overall karyotype instability have not yet been reported in CLL. Here, we studied the telomere status and chromosomal aberrations in a series of CLL patients. A clustering analysis of the data identified groups with distinct cytogenetic and telomere profiles.
This prospective study included 77 patients (57 males and 20 females, median age of 67 years) diagnosed with CLL at the Clermont-Ferrand University Hospital. Blood samples were obtained after informed consent. At the time of sampling, 34 patients were in Binet stage A, 17 in stage B and 26 in stage C. Samples were obtained before any treatment in 60 (77.9%) patients. Among the remaining 17 cases, 16 received no treatment within 6 months prior to the date of sampling.
Karyotype was analyzed after immunostimulation of cell cultures with the CpG-oligonucleotide DSP30 and interleukin 2. Interphase fluorescence in situ hybridization (FISH) was performed with a panel of commercially available probes (Abbott Molecular, Rungis, France) for the detection of trisomy 12 and deletions of 13q14, 11q22.3 (ATM) and 17p13 (p53).
Telomere studies were performed on mononuclear cells (MNCs). Average telomere length was evaluated with quantitative realtime DNA PCR.
2 The method measures the difference between a sample and a reference normal DNA in the ratio of telomere repeat copy number to single-gene copy number (relative T/S ratio). This T/S ratio is proportional to the average telomere length assessed with a classical telomere restriction fragment analysis (r ¼ 0.89; Supplementary Figure S1 ). 
